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Environmental risk factors for osteoporosis
were reviewed at a conference held at the
National Institute for Environmental
Health Sciences 8-9 November 1993. The
conference was co-sponsored by the
National Institute ofArthritis and Mus-
culoskeletal and Skin Disease and the NIH
Office of Research in Women's Health.
The objective of the conference was to
review what is known about risk factors for
osteoporosis and to identify gaps in the
present state of knowledge that might be
addressed by future research. The confer-
ence was divided into two broad themes.
The first session focused on current knowl-
edge regarding etiology, risk factors, and
approaches to clinical and laboratory diag-
nosis. This was followed by three sessions
in which various environmental pollutants
were discussed. Topics selected for review
included environmental agents that inter-
fere with bone and calcium metabolism,
such as the toxic metals lead, cadmium,
aluminum, and fluoride, natural and anti-
estrogens, calcium, and vitamin D.
Bone Metabolism and Osteoporosis
The pathogenesis offractures in osteoporo-
sis is complex; low bone mass is the critical
factor. Microarchitectural abnormalities
(loss ofthe interconnectivity oftrabeculae)
also play a role. A change of 1 SD below
the mean for people without osteoporosis
increases the risk ofbone fracture 1.5-2.5
times. Epidemiology studies have identi-
fied estrogen deficiency and aging as major
risk factors for women, but reasons for
bone loss in males are not understood.
Although 70-80% of peak bone mass
appears to be genetically determined based
on studies of twins, there is no apparent
genetic component to the rate ofbone loss.
There is need for therapies that will
enhance bone formation. Another question
is whether there should be universal estro-
gen therapy for post-menopausal women
and whether we can influence lifestyle
practices such as dietary calcium intake
and exercise in childhood and adolescence,
which are the critical bone-forming years.
Finally, the potential effectiveness of bis-
phosphonates and fluorides in preventing
osteopenia and increasing bone mass needs
to be determined.
The use of absorptiometry and other
techniques for measuring bone density and
assessing fracture risk was reviewed.
Fracture occurrence is related to bone
strength and the load applied to the bone.
This in turn is related to gait speed, soft
tissue padding, and direction and height of
fall. Bone mass (density) is probably the
major determinant of bone strength and
can be measured by a variety of noninva-
sive techniques including ultrasound.
However there are problems of repro-
ducibility (precision), site specificity, and
fracture predictability. Quality of bone is
also an important determinant of fracture
risk, but it cannot be assessed by noninva-
sive methods.
Serum and urinary markers of bone
mineral metabolism can be divided into
those that reflect bone formation and those
that are the product of bone resorption.
The markers, especially osteocalcin, also
have to be understood in the context of
bone remodeling where formation is cou-
pled to resorption and mineral homeosta-
sis. Markers of bone formation that are
most commonly used in research and dini-
cal practice are alkaline phosphatase, osteo-
calcin, and procollagen type 1 peptides.
Alkaline phosphatase suffers from non-
specificity but is still the best test of
osteoblast function, as in Paget's disease of
bone. There are now a number ofimmun-
oassays for osteocalcin, the standard for
measuring osteoblastic activity. Osteo-
calcin generally correlates with alkaline
phosphatase and bone histomorphometry.
Problems are that the function ofosteocal-
cin is not entirely understood, and there is
no international standard regarding speci-
ficity to objectively compare the various
immune assays that are available. Blacks
have higher levels of osteocalcin than
whites. There are also problems with stor-
age of osteocalcin and changes during cir-
cadian rhythms and menstrual cycles.
There is also a contribution of osteocalcin
from platelets that is not related to bone.
Tests for type 1 procollagen peptides are
new and not fully evaluated.
Serum tartrate resistant acid phos-
phatase is a marker for bone resorption but
is tedious to measure because changes are
small. Serum telopeptides of type 1 colla-
gen are also available but are not fully eval-
uated. There are a number of urinary
markers ofbone resorption. The most reli-
able are measurements of D-pyridinoline
and total pyridinoline cross-links. These
correlate with bone densitometry and his-
tomorphometry. Measurements may be
influenced by liver and renal disease. A
serum assay is being developed that will
allow these cross-link measurements to be
included in a battery ofmarkers including
1,25-vitamin D, parathyroid hormone,
and osteocalcin. Other tests of bone
resorption are urinary hydroxyproline
(influence by diet) and urine calcium crea-
tinine ratios. Although any one of these
markers is not sufficient as a predictor or
diagnostic tool ofbone loss, apanel oftests
may define people at risk for excess bone
loss and prompt intervention strategies.
Among experimental models for study-
ing bone disease, the rat may be the pre-
ferred model for a number of reasons. To
be suitable, an animal model should either
develop low bone mass experimentally or
lose bone similarly to the human situation
for osteoporosis. The rat is the most wide-
ly used animal model because methods for
analysis ofrat skeletal tissue are fairly stan-
dard, results from experiments are consis-
tent, and the rat skeleton accurately
reflects disease states found in humans.
Rats also provide a rapid time frame to
assess results of studies. Environmental
effectors can easily be applied to rats.
Finally, the cost of conducting studies on
rats are reasonable. Nevertheless, there are
several questions and problems regarding
the rat, such as lack of evidence of frac-
tures from osteoporosis, lack of a
Haversian system, and lack of suitable
genetic markers, although these may be
provided in time. One criticism is that rat
bones growcontinuously. Nevertheless, rat
bone undergoes modeling and remodeling
similar to humans.
The role ofvitamin D as a factor in the
etiology of osteoporosis was debated.
Clinical trials with vitamin D have shown
promise, especially in selected populations
where vitamin D levels are deficient or
marginal. In normal populations, optimal
dose and risk ofhypercalcemia need to be
defined. A related benefit of vitamin D
may be its immunoregulatory and cell-dif-
ferentiating properties.
Fetal rat calvaria is a common model
for studying bone formation and the
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development of the osteoblast phenotype.
The action of steroid hormones, vitamin
D, glucocorticoids, and estrogens on the
osteoblast can be further clarified using
biochemical and molecular approaches in
vitro. These techniques have shown that
certain hormones affect different genes
depending on the stage ofosteoblast devel-
opment and maturation, secondary tissue
organization, and rate of differentiation.
The osteocalcin gene has been the focus of
attention regarding regulation by steroid
hormones, which may provide some
insight as to therapy ofosteoporosis.
Environmental Risk Factors
Lead
Lead is a potential risk factor for osteo-
porosis because of the central role the
skeleton plays in lead toxicokinetics, and as
well as being a target tissue for lead toxici-
ty. The four presentations emphasized the
diverse effects of lead on bone cell func-
tion, the toxicokinetics and toxicology of
lead in bone, the state ofthe art for nonin-
vasive measurements of lead in tibia and
other bones, and the use of stable isotope
techniques to determine the contribution
ofskeletal lead to blood lead.
Numerous in vitro and in vivo studies
have established the osteoblast and osteo-
clast as targets of lead toxicity. Lead has
complex effects on bone cell function.
First, lead may indirectly alter bone cell
differentiation and function by altering the
plasma levels of calciotropic hormones,
especially 1(,25-dihydroxyvitamin D3 and
parathyroid hormone. Second, lead may
directly alter bone cell function byperturb-
ing the ability of bone cells to respond to
hormonal stimuli such as the synthesis of
bone matrix proteins by perturbing calci-
um-mediated and other sensitive signal
transduction pathways. Third, lead may
directly interfere with hormone and cyto-
kine signal transduction processes and
thereby uncouple osteoblasts and osteo-
clasts from normal paracrine control.
Fourth, lead may directly perturb bone cell
function via biochemical inhibition of
enzymes, resulting in altered cellular ener-
getics. Thus, the cellular and molecular
effects of lead on bone cells are, like the
effects of lead on other biological targets,
complex and multifaceted.
It has long been recognized that the
skeleton contains most ofthe body burden
oflead, and the skeleton is increasingly rec-
ognized as a target organ system for lead
toxicity. The three most likely mechanisms
by which lead might contribute to the
development ofosteoporosis include alter-
ation of 1) peak bone mass, 2) the rate of
bone resorption in older persons, and/or 3)
alteration of the structural integrity of
bone. There are limited experimental stud-
ies addressing each of these potential
mechanisms. Although there is good sup-
port for retardation ofendochondral bone
growth by lead, the long-term conse-
quences ofthis retardation on peak skeletal
mass remain to be established. Unfortun-
ately, the experimental and human studies
are not sufficiently rigorous or detailed to
either support or to eliminate a role for
lead in the pathogenesis ofosteoporosis.
In many circumstances, blood lead,
which primarily reflects recent lead expo-
sure, may be an inadequate indicator of
lead cumulative exposure. Conceptually
and experimentally, bone lead should pro-
vide a superior estimation of cumulative
lead exposure. The noninvasive determina-
tion oflead in bone by X-ray fluorescence
using photons from a radioisotope orX-ray
generator to produce characteristic X-rays
from lead in tibia, calcaneus, and other
bones is a powerful predictor for quantify-
ing past lead exposures and body burdens,
primarily in individuals occupationally
exposed to lead. Improved instrumentation
in electronics and detectors is expected to
provide sufficient sensitivity to be applica-
ble to individuals and populations without
excessive lead exposure. Studies in Balti-
more suggest that a significant number of
women may have bone lead levels >20
mg/g bone. Thus the use of bone lead
measurements as a substitute/supplement
for blood lead measurements as an index of
lead exposure should prove useful in assess-
ing the contribution of lead to diseases
such as osteoporosis, renal disease, and
heart disease.
Mobilization of lead from skeletal
stores during pregnancy and lactation may
constitute a potential threat to the fetus
during critical stages oforgan development.
Stable isotope techniques are powerful for
evaluating the contribution ofskeletal lead
stores to blood lead in humans, ifthere is a
sufficiently large isotopic difference in the
composition of skeletal lead and environ-
mental lead. A pilot study has shown that
migrants to Australia from Eastern Europe
may be a satisfactory population for study,
as the skeletal lead has the stable lead iso-
topic profile of Eastern Europe, while the
Australian environmental lead has a much
different stable isotope profile. Stable isotope
analysis of the blood of these immigrants
provides a reliable estimate of the contri-
bution ofskeletal lead to blood lead during
pregnancy and lactation.
Calcium andEstrogen
Using stable isotope analysis ofnonhuman
primates, it was found that lead was mobi-
lized from bone during pregnancy, produc-
ing internal lead exposure or dosing. Stable
isotope analysis may be useful in determin-
ing which dietary or toxic or physiological
processes are important in the mobilization
process. An ongoing study will investigate
the influence of different levels of dietary
calcium on mobilization/retention ofbone
lead.
A positive calcium effect has been
shown in every study in which calcium
intake was controlled and in which sub-
jects in the immediate post-menopausal
period were excluded. The level of dietary
calcium during the third decade oflife was
important in determining bone density
and risk ofosteoporosis and fractures later
in life. Dietary sodium increases urinary
calcium loss. In the United States there is a
high sodium (salt) usage, which can be a
negative risk factor for calcium metabolism
and development ofosteoporosis. Smoking
and alcohol abuse also decrease bone min-
eral content. Estrogen is an important
determinant of bone density, and calcium
supplementation cannot repair other nutri-
ent deficiencies, offset estrogen depriva-
tion, or neutralize the untoward effects of
unhealthy habits other than low consump-
tion offood sources ofcalcium.
Regarding the regulation of estrogen
receptor expression and responsiveness in
osteoblasts, several steroid hormones affect
bone in different ways. Estrogen is believed
to act directly on estrogen receptors in
bone cells. Levels of estrogen receptor can
be modulated by retinoids influencing
responsiveness to type I collagen and IGF-
1 expression. Results of recent research
suggest an interplay between different hor-
mone signaling pathways, as occurs
between protein kinase C and estrogen in
bone cells.
In experimental models, transient
exposure to estrogen during early develop-
mental periods affects adult bone density
by influencing osteoblast responsiveness to
steroid hormones. Exposure to diethyl-
stilbestrol and other environmental estro-
gens and estrogen agonists can induce
changes in bone density and levels ofestro-
gen during developmental periods and can
dramatically influence cell programming,
resulting in changes in the skeleton during
adulthood. Studies in estrogen-receptor
mutant animals indicate that lower bone
density results from nonfunctional estro-
gen receptors.
Cadmium
The CADMIBEL study, conducted in
Belgium, included a population of 2300
subjects, half of whom lived in areas with
increased environmental exposure to cad-
mium due to their proximity to past and
present zinc smelter operations. Cadmium
in urine (Cd-U), used as an indicator of
cadmium body burden, was shown 50-
85% higher in residents ofNorth Kempen,
the most polluted area, than in residents of
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Charleroi, the least polluted area. With
respect to whether the cadmium exposures
may have caused renal changes, five uri-
nary markers of renal tubular dysfunction
were significantly and positively associated
with Cd-U, namely, retinol-binding pro-
tein (RBP), N-acetyl-glucoaminidase
(NAG), P2-microglobulin, total amino
acids, and calcium. Further, it was estimat-
ed that the risk ofcalciuria and slight tubu-
lar effects was about 10% (that is, a relative
risk of2) when the daily urinary cadmium
exceeded about 2 mg for calciuria, 3 mg
for urinary NAG, RBP, and P2-microglob-
ulin, and about 4 mg for aminoaciduria.
The low value for calciuria indicates that
urinary calcium may be one of the earliest
renal parameters to be affected by increas-
ing cadmium body burden. By these crite-
ria, results also indicated that about 10%
ofthe general population ofBelgium has a
cadmium body burden sufficient to cause
slight changes in calcium metabolism, with
the percentage rising to 40% among 60- to
80-year-old women in North Kempen, the
region ofhighest cadmium exposure.
In response to these results, the follow-
up PHEECAD study is currently under-
way, involving about 1000 subjects from
Hechtel-Eksel (rural control area) and
North Kempen (rural cadmium exposure
area). One question that PHEECAD
addresses is whether the increased calciuria
and serum alkaline phosphatase activity
seen in the CADMIBEL study are associat-
ed with an increased risk ofabnormal bone
metabolism, as measured by forearm den-
sitometry and serum and urine markers of
bone remodeling.
Finally, in a group of 37 chronically
exposed cadmium workers and 43 matched
controls, with workers having Cd-U values
five times higher than controls (5.4 versus
0.7 pg/g creatinine), urinary eicoanoids
and sodium, but not calcium, were weakly
but positively correlated with Cd-U.
Because spot urine samples were collected,
these results do not conclusively support or
contradict results of the CADMIBEL
study, in which 24-hr urine samples were
taken.
The first ofthree studies on osteopenia
and Itai-Itai disease in Japan involved 234
women and men with cadmium-induced
renal dysfunction, including 28 women
with Itai-Itai disease, along with 110
women and men from control, nonpollut-
ed areas. The mean age was 70 years, and
Cd-U values were 8-11 mg/g creatinine
for exposed and 2.5 mg/g creatinine for
nonexposed subjects. Results showed that
indices ofbone mineral content and densi-
ty, obtained by microdensitometry, were
significantly lower in cadmium-exposed
men and women with renal dysfunction
than in the nonexposed subjects. The sec-
ond study involved 203 cadmium-exposed
subjects with renal dysfunction and 80
nonexposed subjects. Multivariate analyses
performed to evaluate relationships be-
tween parameters ofrenal dysfunction and
multiple measures ofbone mineral content
and density obtained by microdensitome-
try showed a significant relationship
between the extent of renal dysfunction
and osteopenia.
The third study demonstrated that, as
cadmium-induced renal damage increased
(higher urinary 02-microglobulin and
lower %TRP), concentrations of
1,25(OH)2-vitamin D in serum decreased,
with a concomitant increase in parathyroid
hormone. Results indicated that distur-
bances in vitamin D and parathyroid hor-
mone may play a role in cadmium-induced
bone damage. The extensive database pre-
sented essentially showed that, in both
men and women exposed to cadmium to
the point where they have cadmium-
induced renal damage, the extent of their
renal damage is directly related to the
extent of their osteopenia, implying a
causal role of their renal damage in the
development ofosteopenia.
A model for osteoporosis in dogs in-
duced by cadmium and estrogen deficits
was described. A database of studies in
mice demonstrates that the female skeleton
is sensitized to demineralizing effects of
dietary cadmium both during periods of
pregnancy and lactation and after removal
ofthe ovaries (to simulate menopausal hor-
monal changes in humans). Studies with
45Ca showed that the release of45Ca from
bone occurred within 96 hr of the start of
cadmium exposure and therefore preceded
the renal damage characterized to occur
after longer periods of exposure to dietary
cadmium.
A study to evaluate combined effects of
estrogen depletion (by ovariectomy) and
cadmium exposure on bone of elderly
female beagles (7-9 years old) whose skele-
tons were prelabeled with 45Ca showed
that serum 45Ca levels were significantly
increased within 96 hr ofexposure to cad-
mium in drinking water (15 mg/1); the
response was greatest in ovariectomized
animals and was not mediated by changes
in the calciotropic hormones [1,25(OH)2
vitamin D, parathyroid hormone, calci-
tonin]. Mean blood cadmium concentra-
tions were 3-8 mg/l during the earliest
bone response and 13-15 mg/l 6 months
later, providing a way to relate results to
human exposures. Sequential in vivo dual
photon absorptiometry measurements of
tibia and lumbar vertebral bone mineral
density (BMD) were made in each animal.
The greatest decrease in BMD occurred in
the ovariectomized animals exposed to cad-
mium for 7 months (-7% to -15%). Early
histomorphometric analyses indicate that
soon after cadmium exposure (4 weeks of
drinking water Cd) and 3.5 months after
ovariectomy, bone formation parameters
were increased 1.5- to 4-fold by hormone
depletion, independent of cadmium expo-
sure. Histomorphometric analyses are con-
tinuing to ultimately demonstrate whether
bone changes observed by in vivo BMD
measurements and serum 5Ca analyses
correlate with changes in bone formation
and resorption.
Aluminum
Osteopenic aluminum-related bone disor-
ders, which include the renal osteodys-
trophic diseases low-turnover osteomalacia
(LTOM) and aplastic bone disease occur
in up to 20 and 33%, respectively, of the
dialysis-dependent patients in North
America. There are compelling data in
support of a role of aluminum in the
etiopathology of these diseases, including
clinical data showing an association ofalu-
minum exposure with disease incidence, an
in vivo rat model for LTOM associated
with aluminum exposure, and an in vitro
system supporting an osteopenic response
to aluminum. However, results of ambi-
tious studies of straightforward design in
beagle dogs gave contradicting results. In
these experiments, osteomalacia was
induced in dogs by giving them a diet defi-
cient in both vitamin D and calcium. The
dogs received aluminum by intravenous
injection (3 mg/kg/week), resulting in
deposition of aluminum on the bone-
osteoid interface (shown histologically by
bone biopsy), as occurs in renal dialysis
patients. The dogs were then put on a
replete diet to see if the aluminum on the
bone surface would impede remineraliza-
tion. Results clearly showed that bone
healed with no problem directly over the
layer ofaluminum.
In a second study, dogs were injected
with aluminum at 0.75 or 1.25 mg/kg/day
three times per week for 16 weeks. At both
doses, there was evidence ofnew bone for-
mation at 8 weeks, with arborization of
trabeculae and an increase in bone volume
at the higher dose. This response did not
occur in parathyroidectomized animals.
When the dogs were taken offaluminum,
the woven, osteoid-containing bone
(formed in the presence of aluminum)
mineralized. In addition, there was an
increased proliferation of osteoblastlike
MC3T3E1 cells in response to aluminum,
in keepingwith the in vivo findings.
Fluoride
In a detailed review ofthe epidemiological
database for the role of fluoride in the
pathogenesis ofosteoporosis, two questions
were evaluated: Is the current EPA maxi-
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mum permitted level of fluoride in drink-
ing water of4 mg/l too high? Should fluo-
ride be approved for treatment of osteo-
porosis? Although some studies have
shown small increases in hip fracture rate
with increasing fluoride intake from natur-
al or adjusted sources offluoride in drink-
ing water, overall conclusions were that, at
levels (1 mg/l) typically used in artificially
fluoridated or many naturally fluoridated
water supplies, there is weak or no evi-
dence that fluoride induces more bone
fractures than in nonfluoridated drinking
water. It was also concluded that there is
no basis to recommend that EPA lower the
current 4 mg/l maximum containment
level.
With respect to studies of fluoride for
treatment of osteoporosis, the design of
early studies was criticized because they
were not randomized, controlled clinical
trials. However, four recent randomized
studies showed that fluoride treatment did
not cause a statistically significant reduc-
tion in vertebral fractures. A recent study is
being published by Pak et al. in which
sodium fluoride administered in a slow
release form significantly reduced vertebral
fractures, indicating that slow-release fluo-
ride may be a promising treatment for
osteoporosis.
In the final two sessions of the confer-
ence, government activities on osteoporosis
were reviewed. The National Institute of
Arthritis and Metabolic and Skin Disease
is supporting a study of osteoporotic frac-
tures. This is the largest cohort study
focused on osteoporosis and is currently
collecting data on risk factors for fractures.
Information collected to date has provided
information about the etiology offalls and
fractures, the sites in the bodywhere osteo-
porotic fractures occur most commonly,
and the role ofbone density as a risk factor
for fractures. The Women's Health initia-
tive, the largest trans-National Institutes of
Health study, will investigate osteoporosis,
as well as cardiovascular disease and breast
cancer in a large multicenter trial and
observational study. Two of the interven-
tions will have particular relevance to
osteoporosis: hormone replacement and
calcium/vitamin D supplementation. The
study will investigate the significance and
clinical applications of new genetic and
biochemical markers of osteoporosis such
as osteocalcin.
Conclusions
The potential link between lead exposure
and osteoporosis is reasonable, based on
our current understanding of osteoporosis
and lead toxicity. Human and animal stud-
ies provide strong evidence for effects of
lead on the endocrine regulation of bone
mineral homeostasis, bone growth, and
skeletal toxicity. These studies are in
accord with current understanding of the
cellular and molecular mechanisms oflead
toxicity in bone and other cells.
Environmental levels of cadmium
exposure in areas of previous contamina-
tion from smelter activities may affect cal-
cium metabolism in the kidney, resulting
in small increases in urinary calcium excre-
tion. Epidemiology studies from Japan
demonstrate that once renal tubular dys-
function appears in response to cadmium
exposure, hypercalciuria and osteopenia
follow. This response may be mediated by
decreases in circulating levels of 1,25
(OH)2-vitamin D, with concomitant
increases in parathyroid hormone. Results
ofexperimental studies support the conclu-
sion that cadmium causes bone loss early
after the start ofdietary cadmium exposure
(within 96 hr), before the start of cadmi-
um-induced renal damage typified by
increased urinary excretion of NAG, I2-
microglobulin, and amino acids. In addi-
tion, the bone demineralization response
to cadmium is increased in females during
pregnancy and lactation and in elderly
females after menopausal hormone deple-
tion, making females at greater risk ofcad-
mium-induced bone loss than males.
The relationship between aluminum
and bone disease, particularly osteoporosis,
is currently not clear. The decrease in cir-
culating parathyroid hormone concentra-
tions that accompanies both low turnover
osteomalacia and aplastic bone disease may
be the result of an aluminum-mediated
decrease in parathyroid hormone levels.
However, the connection between alu-
minum exposure and bone disease should
not be underestimated. There is seldom a
patient with clear evidence of aluminum
deposition in bone who does not also have
bone disease.
Fluoride at levels found in drinking
water does not appear to be associated with
increases in bone fractures, and at intake
levels about 10 times higher (50-80
mg/day), fluoride may decrease fractures
when given in a slow release form.
Adequate dietary calcium is important
early in life for bone formation, but calci-
um supplementation cannot repair other
nutrient deficiencies or offset estrogen
deprivation as occurs in the immediate
postmenopausal period. Dietary sodium
increases urinarycalcium excretion.
Experimental studies suggest that there
is direct estrogen-receptor-mediated action
that influences bone density. Exposure to
diethylstilbestrol and other environmental
estrogens and estrogen agonists early in life
may influence cell programming in estro-
gen target tissues including bone and
change the risk for osteoporosis later in
life.
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Future Research Directions
There are few experimental and clinical
studies that are specifically designed to
investigate the contribution ofthe environ-
mental risk factors for osteoporosis identi-
fied at this conference. Research needs
include the use of animal models to more
clearly define the effects of these metals,
particularly lead and cadmium, on the
conservation of bone mineral (using tracer
and histomorphometry) and to clarify
dose-response relationships and exposure
timing/duration factors most critical to the
skeletal toxicity of these metals. There is a
need to further investigate metal/environ-
mental effects on bone cell function,
including the endocrine, paracrine, and
autocrine regulation, and to identify con-
founding and contributing factors that
might exacerbate or minimize the develop-
ment of osteoporosis (diet, genetics, preg-
nancy, lactation, etc.). There is a need to
apply biomarkers for skeletal dysfunction
in studies ofeffects ofenvironmental cont-
aminants on bone.
Because the etiology of osteoporosis is
largely unknown and the risk factors are
numerous, sophisticated epidemiological
studies are also needed to establish the exis-
tence of a relationship between diseases
and toxic metal exposures, particularly lead
and cadmium. Studies should be conduct-
ed on metal exposure during childhood
and adolescence that might alter peak bone
mass and occupational exposure to metals
culminating in high bone levels that might
modulate bone loss.
Finally, it is important to consider the
potential role ofosteoporosis in the devel-
opment of lead toxicity. Epidemiological
studies suggest that lead is released from
the skeleton to blood during bone loss.
Thus, studies to determine the magnitude
ofskeletal lead release and the contribution
ofskeletal lead to lead toxicity ofthe aging
nervous, renal, immune, and endocrine
systems should be considered. Other
research questions are whether the aging
nervous system, like developing systems, is
more susceptible to lead and whether expo-
sure to lead and other toxic metals such as
cadmium, and aluminum, and fluoride
reduce the reserve capacity of organs and
tissues and thereby exacerbate the aging
process or the consequences ofaging.
Although the beneficial effects of
dietary calcium supplementation in young
people are recognized, there is a need to
learn more about the role of calcium sup-
plementation above present dietary re-
quirements on bone metabolism and its
potential role in enhancing bone density
later in life (post-menopause).
Studies on the mechanism ofaction of
estrogens on receptors in bone should be
continued, with emphasis on natural estro-
gens and estrogen agonists occurring in the
environment. The time course of any
effects have to be evaluated as well.
Finally, studies of other etiologic fac-
tors in osteoporosis should include rela-
tionships to environmental factors that
presumably can be controlled.
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